Below you will find the latest press releases from Evolva. You are also welcome to dive into the archive and browse our press releases from there as well:
Latest Press Releases
Reinach, Switzerland, 5 December 2013 – Evolva Holding SA (SIX: EVE) today announced that it will participate in the EU-funded PROMYS research project. The project has a duration of four years and a total EU funding of EUR 7.2 million (CHF 8.9 million), of which Evolva’s share is 9.8%.
Reinach, Switzerland, 14 November 2013 – Evolva Holding SA (SIX: EVE) announces that its collaboration with International Flavors & Fragrances Inc. (IFF), announced in May 2012 and targeted at an undisclosed flavouring ingredient, will be discontinued in early 2014.
Reinach, Switzerland, 7 October 2013 – Evolva Holding SA (SIX: EVE) and Serodus ASA (Oslo, Norway) today announced that they have signed a binding term sheet for the clinical development of EV-077, Evolva’s compound targeted at diabetic nephropathy (progressive kidney disease caused by diabetes).
Reinach, Switzerland, 24 September 2013 – The US Defense Threat Reduction Agency (DTRA) has announced that it has selected Evolva to enter into contract negotiations regarding possible preclinical funding for Evolva’s antibiotic compound GC-072 (the lead compound in Evolva’s EV-035 series) under the Transformational Medical Technologies Initiative (TMTI).
MINNEAPOLIS and REINACH, SWITZERLAND – Cargill and Evolva Holding SA (SIX: EVE) announced today that their development program for fermentation-based steviol glycosides is moving into pilot scale ahead of schedule, potentially making it available for commercialization sooner than expected.
Reinach, Switzerland, 22 August 2013 – Evolva Holding SA (SIX: EVE) today announced its financial results for the period 1 January to 30 June 2013. The condensed half-year accounts are available on Evolva’s website.
Reinach, Switzerland, 8 August 2013 – Evolva Holding SA (SIX: EVE) announced today that, following Evolva’s request, the Japanese Ministry of Health, Labor and Welfare has issued a notice that resveratrol should be classified into the Non-drug material group.
Reinach, Switzerland, 7 May 2013 – The Annual General Meeting of Evolva Holding SA (SIX: EVE) has approved all proposals put forward by the Board of Directors.
Reinach, Switzerland, 9 April 2013 – Evolva Holding SA (SIX: EVE) today announced its financial results for the period 1 January to 31 December 2012.
Reinach, Switzerland, 27 March 2013 — Evolva Holding SA (SIX: EVE, “Evolva”) today reports the completion of the capital increase that was announced on 6 March 2013. The offering provides Evolva with gross proceeds of CHF 31.3 million before transaction costs.
- 1 of 11
- next ›